Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Randomized, Controlled, Observer-Blind, Dose-Ranging Study of Acellular Pertussis and Tetanus-Diptheria-Acellular Pertussis Booster Vaccine in Adults Ages 18 to 40 Years.

NCT01529645 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01529645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01529645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Randomized, Controlled, Observer-Blind, Dose-Ranging Study of Acellular Pertussis and Tetanus-Diptheria-Acellular Pertussis Booster Vaccine in Adults Ages 18 to 40 Years.
Lead sponsor
Novartis Vaccines
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2012
Completion date
July 31, 2013
Enrollment
420 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, lockjaw, pertussis, tetanus, whooping cough